Alder BioPharmaceuticals brings together the brightest minds from leading companies. Together, we possess the operations, development and commercialization experience to bring novel therapies to market.
Chief Executive Officer
Prior to joining Alder BioPharmaceuticals, Mr. Azelby was Juno Therapeutics’ Executive Vice President, Chief Commercial Officer reporting to the CEO where he was a standing member of Juno’s Executive Team participating in the management of all aspects of Juno’s operations and was personally accountable for leading and developing Juno’s commercial capabilities. In addition to the commercial function, Mr. Azelby oversaw and led the development of Juno’s project management, corporate affairs and medical science liaison functions. Before Juno, Mr. Azelby was the Vice President and General Manager of Amgen’s US Oncology Business Unit representing $6.5 Billion. Over his 15 year career with Amgen, Mr. Azelby held numerous sales and marketing positions including Vice President U.S. Oncology Sales, Vice President of North American Commercial Operations, General Manager, Amgen Netherlands, Senior Marketing Director, etc. Prior to Amgen, Mr. Azelby was Chief Operating Officer for a venture-capital-backed early-stage company specializing in catastrophic event medical management. Mr. Azelby also held the position of Chief Financial Officer for a subsidiary of Oxford Health Plans and was also a Professional Sales Representative for GlaxoWellcome. Mr. Azelby received his undergraduate degrees in Economics and Religious Studies from the University of Virginia and his Master of Business Administration from Harvard University.
Chief Medical Officer
Dr. Streck brings more than 25 years of experience in drug development, regulatory and medical affairs leadership across both large and small publicly traded biopharmaceutical companies. He joins Alder from Insmed Incorporated, where he served as chief medical officer and played an instrumental role as a member of the executive leadership team, successfully leading the Arikayce® regulatory filing, approval and launch. Prior to Insmed, Dr. Streck was GlaxoSmithKline (GSK) plc’s group vice president and global medical lead of the Immuno-inflammation division responsible for the immunology portfolio strategy, including Benlysta® and sirukumab. Before GSK, Dr. Streck spent eight years at Shire plc, culminating in his role as group vice president, clinical development for hematology, gastrointestinal and internal medicine. In this role, Dr. Streck led a team of 50 people and was responsible for thirteen clinical trial programs and regulatory filings across various product lifecycle stages. Prior to Shire plc, Dr. Streck held a variety of medical affairs and commercial roles over five years with Amgen Inc.
Chief Financial Officer
Mr. Campoy has served as the Chief Financial Officer of Alder BioPharmaceuticals since December 2018. Mr. Campoy holds nearly 30 years of financial leadership and expertise across global publicly traded companies, including more than 20 years in the biopharmaceutical and healthcare sectors. Prior to joining Alder, Mr. Campoy served as Vice President of Finance, International at Allergan plc, where he led the strategic, operational and financial decision-making for the region and successfully designed and implemented new financial processes and an organizational structure. Prior to this position, Mr. Campoy spent 18 years at Eli Lilly and Company, where he served multiple financial leadership positions, including Chief Financial Officer, Eli Lilly Japan K.K. and U.S. Senior Director of Finance and Chief Financial Officer for the U.S. Specialty Sales and Marketing team. He most recently served as Partner of Think Forwards, a financial consulting firm focused on providing innovative solutions and transformational initiatives to drive growth. He previously served on the Board of TP Orthodontics from 2006 to 2010. Mr. Campoy is a Certified Management Accountant (CMA). He holds an MBA in Finance and Decision Information Systems from Indiana University and a BS in Management from Faculdade C.C. Administracao de Tupa, in São Paulo, Brazil.
Chief Commercial Officer
Ms. Dac brings more than 25 years of U.S. and global commercial experience with both large and small publicly traded biopharmaceutical companies, and has a track record of successfully launching multiple novel neurology products in competitive markets. Ms. Dac also has extensive expertise across all commercial functions including marketing, market access and promotion, sales, pipeline management, business development and partnerships. Before joining Alder, Ms. Dac served as vice president of global specialty commercial development at AbbVie and played an instrumental role in driving the optimization of assets within the specialty pipeline portfolio, including the in-licensing and commercial development of the global neuroscience, women’s health, virology and cystic fibrosis portfolios. Prior to AbbVie, Ms. Dac held several roles of increasing responsibility at Novartis, where she was head of the Multiple Sclerosis (MS) franchise, building the sales organization that successfully launched Gilenya®, Extavia® and Ilaris®. Ms. Dac also spent several years in marketing roles including leading marketing for Biogen’s MS products and as well as for Aricept® at Pfizer. Previously, Ms. Dac spent several years in marketing and sales roles at Johnson & Johnson and Eli Lilly and Company.
Chief Operating Officer
Ms. Lavelle has served as the Chief Operating Officer of Alder BioPharmaceuticals since April 2018. She has more than 20 years of cross-functional experience leading strategic and operational initiatives in the biopharmaceutical industry. Before joining Alder, Ms. Lavelle worked at Amgen for 15 years in a variety of roles in the Corporate Development, Finance and Commercial organizations. Her most recent role was General Manager of Amgen’s Taiwan affiliate where she managed a portfolio of six commercialized products. Prior to that, Ms. Lavelle worked in Hong Kong as an Executive Director for the Japan Asia-Pacific region during its initial build. She began her career in 1998 as an investment banker in the healthcare group at Merrill Lynch & Co. Ms. Lavelle holds a Bachelor of Arts in Economics from Yale University.
Dr. Smith has served as our Managing Director since March 2017. He cofounded the company in January 2004. Dr. Smith served as our Senior Vice President, Translational Medicine from 2012 to March 2017 and in other senior management positions from April 2004 to 2012. From 1999 to 2004, Dr. Smith served as Senior Director of Medical Research for Celltech R&D, where he was responsible for planning and managing the CDP870 anti-TNF clinical trials for RA as well as several other key autoimmune clinical development programs. From 1997 to 1999, he served as Medical Director at Simbec Research Ltd., a contract research organization. From 1995 to 1997, Dr. Smith served as Head of Clinical Pharmacology at Hoechst Marion Roussel Ltd., a pharmaceutical company. From 1994 to 1995, Dr. Smith served as a Senior Clinical Physician at the Proctor and Gamble Company, a publicly-traded consumer products company, and from 1989 to 1994, he served as a Senior Research Physician in the clinical pharmacology department at Glaxo Research and Development Ltd., now a division of GlaxoSmithKline plc, a healthcare company. Dr. Smith holds an M.D. from the University of London and is a Fellow of the Royal College of Physicians in London.
Executive Vice President, Pharmaceutical Operations
Mr. Hassler joined Alder in 2014 and has served as our Executive Vice President of Pharmaceutical Operations since February 2018. Prior to joining Alder BioPharmaceuticals, Mr. Hassler served as Vice President of Operations and Finance and Chief Operating Officer for seven years at Seattle Biomedical Research Institute, working on the fight against global infectious diseases. From 1995 to 2007, he served in various leadership positions at Amgen including Process Development, Quality Control, and Quality Assurance. In addition, he played major roles in Amgen’s acquisitions of both Immunex and Abgenix. From 1983 to 1995, Mr. Hassler served in a variety of research and development positions at Synergen in Boulder, Colorado. Mr. Hassler holds a B.S. in Microbiology from Indiana University and an M.S. in Microbiology from Colorado State University.
Executive Vice President & General Counsel
Mr. Bucher has served as our Executive Vice President and General Counsel since February 2019 and served as of our Senior Vice President and General Counsel from January 2016 to January 2019. Prior to joining Alder BioPharmaceuticals, Mr. Bucher served as Vice President, Corporate Legal Affairs and Secretary, and as the Corporate Compliance Officer, of Exelixis, Inc., a Nasdaq-listed biopharmaceutical company, which he joined in 2007. From 1991 to 2007, Mr. Bucher practiced as a corporate attorney at the international law firm Shearman & Sterling LLP, becoming a partner in 2001. Mr. Bucher holds a J.D. with distinction from Emory University School of Law, and a B.A. in Biology from Colgate University.
Senior Vice President, Quality
Ms. Vahratian has served as our Senior Vice President of Quality since 2017. Prior to joining Alder as Vice President, Quality in 2015, Ms. Vahratian served as Principal Quality Consultant for ten years at AV BioPharma Consulting, serving the greater biopharmaceutical industry in support of innovator biologics drug development and regulatory product registrations. While at Immunex Corporation (now Amgen) from 1989 to 2002, she served as VP, Quality and in various management positions, where she was instrumental in gaining FDA approval of Enbrel® and managing Enbrel® commercial operations at multiple sites worldwide. Ms. Vahratian supported Wyeth (now Pfizer) in their international registration of Enbrel® in the European Union, and she has been involved in more than 15 IND applications and two FDA marketing authorization drug approvals. Ms. Vahratian holds a B.S. in Biology and Psychology from Hope College.
Senior Vice President, Regulatory Affairs
Ms. Yeager has more than 25 years of management responsibility for regulatory and marketing activities in the pharmaceutical, medical device and biotechnology fields. Prior to joining Alder, she co-led development and approval of Tobramycin Inhalation Solution (TOBI®) and Aztreonam Inhalation Solution (Cayston®) and played an instrumental role in gaining on multiple appeals, including the approval for Cayston after both the EMA and FDA rejected the initial applications. Ms. Yeager’s broad experience in product development includes management positions with Gilead Sciences, Becton Dickinson and other Fortune 500 corporations, as well as smaller, specialized biotechnology ventures. In these roles, she has provided key leadership through all phases of drug, device and combination product development both in the US and overseas. Most recently, Ms. Yeager held positions as Chief Regulatory Officer, Breath Therapeutics, and Chief Operating Officer at Cardeas Pharma. Prior to joining Breath and Cardeas, Ms. Yeager was Vice President of Regulatory Affairs at Corus Pharma and Gilead Sciences for nine years, guiding multiple regulatory and quality assurance activities for small molecule products. Her key responsibilities in these roles included provision of nonclinical, clinical and CMC regulatory strategies and managing pre- and post-approval regulatory activities for compliance with FDA and world health agency standards. Ms. Yeager received her B.A. degree in Human Biology from Stanford University and her J.D. degree from Santa Clara University. She currently holds positions on scientific advisory boards for start-up entities and is a lead board member of several nonprofit organizations.
Vice President, Neurology
Dr. Cady has served as Vice President, Neurology of Alder BioPharmaceuticals since June 2016. Prior to joining Alder, Dr. Cady served as the Medical Director of the Headache Care Center and was the founder of Clinvest Research and Primary Care Network, a CME education company. He also served as Medical Director for the Shealy Institute in Springfield, Missouri. During his career, Dr. Cady has authored over 250 scientific papers and received numerous awards, including the Harold Wolff Award in 2000. Dr. Cady is also a Fellow of the American Headache Society and a member of the Board of Directors for the National Headache Foundation. Dr. Cady holds a bachelor’s degree from Drake University in Des Moines, Iowa and received his medical degree from the Mayo Medical School in Rochester, Minnesota. He then completed his residency in family practice at Mayo Clinic Health System – Franciscan Healthcare in La Crosse, Wisconsin.
Vice President, Medical Affairs
Dr. Kassel was appointed as the Vice President, Medical Affairs of Alder BioPharmaceuticals in April 2017, having served previously as a consultant to the company. He has more than 20 years of experience as a clinician and in medical affairs leadership. Before joining Alder, Dr. Kassel spent 15 years with medical affairs at Allergan, Inc, supporting the development and approval of onabotulinumtoxinA for the treatment of chronic migraine. Most recently he served as Senior Director, Payer and Health Outcomes, Regional Scientific Services of Allergan, where he managed the payer facing medical affairs strategy across six therapeutic areas and accounting for $500M in portfolio sales. Dr. Kassel began his career as a clinical pharmacist in critical care at Illinois Masonic Hospital in Chicago, Illinois. Dr. Kassel is a residency trained clinical pharmacist who earned his doctorate in pharmacy degree from the University of Illinois in Chicago after completing undergraduate degrees in biology and chemistry at Illinois State University.
Vice President, Human Resources
Ms. Malcolm joined Alder BioPharmaceuticals in June 2008 and was appointed Vice President of Human Resources in January 2018. Altogether, Ms. Malcolm has more than 20 years of experience in biopharmaceutical and healthcare human resources. Prior to joining Alder, she served as a Human Resources Consultant at Seattle Children’s Hospital Research Institute, and previously held human resources positions at Seattle Genetics, Chiron Corporation, and Pathogenesis Corporation. Ms. Malcolm has been a longtime participant in the Life Science Washington HR Group, an industry networking association, including serving as a past Steering Committee Co-Chair. Ms. Malcolm holds a Bachelor of Arts in Liberal Arts from St. John’s College in Santa Fe, New Mexico.